Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000352306 | SCV000335975 | uncertain significance | not provided | 2015-10-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855127 | SCV002315964 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2024-09-17 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 3847 of the SYNE2 protein (p.Asp3847Asn). This variant is present in population databases (rs376684112, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. ClinVar contains an entry for this variant (Variation ID: 283704). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Athena Diagnostics | RCV000352306 | SCV002771340 | uncertain significance | not provided | 2021-09-13 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001855127 | SCV003818202 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2019-04-11 | criteria provided, single submitter | clinical testing |